Printer Friendly

CYTOGEN'S FIRST CANCER THERAPY AGENT ENTERS PHASE II CLINICAL TRIALS

CYTOGEN'S FIRST CANCER THERAPY AGENT ENTERS PHASE II CLINICAL TRIALS
 PRINCETON, N.J., July 14 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) announced today the initiation of Phase II human clinical studies for OncoRad(R) ovarian, the company's first cancer therapeutic product.
 The Phase II studies will involve ovarian cancer patients with measurable disease, with the objective to demonstrate consistent therapeutic effects.
 The positive findings of the Phase I study demonstrate that OncoRad ovarian can be safely administered to ovarian cancer patients, with up to 35 millicuries of radioisotope Yttrium 90, without evidence of side effects or serious adverse reactions. In addition, three patients experienced tumor response, including two complete and durable remissions.
 "Ovarian cancer is commonly referred to as a 'silent killer,' due to the unobtrusive and, commonly, undetected spread of the disease in a woman's body," stated Cytogen President Thomas J. McKearn. "The American Cancer Society estimates that this disease will strike 21,000 and kill 13,000 women in the U.S. this year. Since none of the commonly observed side effects of conventional chemotherapy (i.e., nausea, vomiting, hair loss, loss of peripheral nerve function, or increased susceptibility to infection) have been observed with OncoRad ovarian, the drug may therefore hold the promise of being a very well tolerated adjunctive treatment for ovarian cancer."
 Cytogen is a biopharmaceutical company engaged in the development of proprietary systems utilizing monoclonal antibodies for the targeted delivery of diagnostic and therapeutic substances in human health care applications. Cytogen uses its patented and proprietary antibody "linker" technology to develop specific cancer diagnostic imaging and cancer therapeutic products, as well as certain other products.
 /delval/
 -0- 7/14/92
 /CONTACT: Martin D. Cleary, group vice president of Cytogen, 609-987-8221/
 (CYTO) CO: Cytogen Corporation ST: New Jersey IN: MTC SU:


MP-JS -- PH013 -- 9031 07/14/92 10:50 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 14, 1992
Words:304
Previous Article:UTILITIES AFFIRM COMMITMENT TO POWER PROJECT
Next Article:COVENANT ENVIRONMENTAL BEGINS PRODUCTION OF MOBILE RETORT RECYCLING SYSTEM
Topics:


Related Articles
CYTOGEN AND CYTORAD PROSTATE CANCER IMAGING AGENT ENTERS PHASE III OF HUMAN TESTING
CYTOGEN ACQUIRES RIGHTS TO PAIN RELIEF AGENT FOR BONE CANCER
CYTOGEN UPDATES STOCKHOLDERS ON MARKETING OF ONCOSCINT(R) CR/OV, PRODUCT DEVELOPMENT ACTIVITIES & CYTORAD DEVELOPMENTS
Progenics and Cytogen Announce Progress on Vaccine and Antibody Therapies for Prostate Cancer.
Progenics Announces News On Cancer Vaccine Trial.
Progenics and Cytogen Select Therapeutic Prostate Cancer Vaccine for Human Testing.
Progenics Pharmaceuticals and Cytogen Create Fully Human Monoclonal Antibodies for Prostate Cancer Therapy through Collaboration With Abgenix.
Progenics and Cytogen Report New Discoveries on Molecular Structure of Key Prostate Cancer Marker.
Results of PI-88 Phase II Clinical Trial in Melanoma Presented at ASCO.
Reportlinker Adds World Cancer Therapies Market Report.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters